Platensimycin (PTM) and platencin (PTN) are potent and selective inhibitors of bacterial and mammalian fatty acid synthases and have emerged as promising drug leads for both antibacterial and antidiabetic therapies. Comparative analysis of the PTM and PTN biosynthetic machineries in
Streptomyces platensis
MA7327 and MA7339 revealed that the divergence of PTM and PTN biosynthesis is controlled by dedicated
ent
-kaurene and
ent
-atiserene synthases, the latter of which represents a new pathway for diterpenoid biosynthesis. The PTM and PTN biosynthetic machineries provide a rare glimpse at how secondary metabolic pathway evolution increases natural product structural diversity and support the wisdom of applying combinatorial biosynthesis methods for the generation of novel PTM and/or PTN analogues, thereby facilitating drug development efforts based on these privileged natural product scaffolds.
Platensimycin(PTM)和platencin(PTN)是细菌和哺乳动物脂肪酸合成酶的有效和选择性抑制剂,并已成为有前途的抗菌和抗糖尿病治疗药物前体。对Streptomyces platensis MA7327和MA7339中PTM和PTN生物合成机制的比较分析表明,PTM和PTN生物合成的分化是由专门的ent-kaurene和ent-atiserene合成酶控制的,后者代表了二萜类化合物生物合成的新途径。PTM和PTN生物合成机制提供了一个罕见的机会,展示了次生代谢途径的进化如何增加天然产物结构多样性,并支持应用组合生物合成方法生成新的PTM和/或PTN类似物的智慧,从而促进基于这些特权天然产物支架的药物开发工作。